US7301021B2
(en)
|
1997-07-02 |
2007-11-27 |
Smithkline Beecham Corporation |
Substituted imidazole compounds
|
US7517880B2
(en)
*
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
US7329670B1
(en)
*
|
1997-12-22 |
2008-02-12 |
Bayer Pharmaceuticals Corporation |
Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
|
WO2000010563A1
(en)
|
1998-08-20 |
2000-03-02 |
Smithkline Beecham Corporation |
Novel substituted triazole compounds
|
US6525069B1
(en)
|
1998-12-18 |
2003-02-25 |
Bristol-Myers Squibb Pharma Co. |
N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
|
RU2319693C9
(ru)
*
|
1999-01-13 |
2008-08-20 |
Байер Копэрейшн |
Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
|
EP1140840B1
(en)
*
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
EP1158985B1
(en)
|
1999-01-13 |
2011-12-28 |
Bayer HealthCare LLC |
OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
|
MXPA01008440A
(es)
|
1999-02-22 |
2002-04-24 |
Boehringer Ingelheim Pharma |
Derivados heterociclicos policiclos como agentes anti-inflamatorios..
|
ATE278674T1
(de)
|
1999-03-12 |
2004-10-15 |
Boehringer Ingelheim Pharma |
Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
|
WO2000055152A1
(en)
*
|
1999-03-12 |
2000-09-21 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as anti-inflammatory agents
|
ES2253233T3
(es)
*
|
1999-07-09 |
2006-06-01 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Procedimiento para sintesis de compuestos de urea heteroaril sustituidos.
|
US6759410B1
(en)
*
|
1999-11-23 |
2004-07-06 |
Smithline Beecham Corporation |
3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
|
US6525046B1
(en)
|
2000-01-18 |
2003-02-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Aromatic heterocyclic compounds as antiinflammatory agents
|
US6608052B2
(en)
|
2000-02-16 |
2003-08-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compounds useful as anti-inflammatory agents
|
JP2004516238A
(ja)
*
|
2000-06-21 |
2004-06-03 |
ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー |
ケモカイン受容体活性調節剤としてのn−ウレイドアルキル−ピペリジン
|
US6565880B2
(en)
|
2000-07-24 |
2003-05-20 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea
|
DE60134679D1
(de)
|
2000-10-20 |
2008-08-14 |
Eisai R&D Man Co Ltd |
Stickstoff enthaltende aromatische Heterozyklen
|
WO2002066442A1
(en)
*
|
2001-02-15 |
2002-08-29 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Process for synthesis of heteroaryl-substituted urea compounds useful as antiinflammatory agents
|
MXPA03010487A
(es)
*
|
2001-05-16 |
2004-03-09 |
Boehringer Ingelheim Pharma |
Derivados de diarilurea utiles como agentes antiinflamatorios.
|
EP1395561A1
(en)
|
2001-05-25 |
2004-03-10 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Carbamate and oxamide compounds as inhibitors of cytokine production
|
CA2446193C
(en)
|
2001-06-05 |
2011-11-01 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
1,4-disubstituted benzo-fused cycloalkyl urea compounds
|
EP1709965A3
(en)
|
2001-07-11 |
2006-12-27 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating cytokine mediate diseases
|
US6808721B2
(en)
*
|
2001-07-11 |
2004-10-26 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods for coating pharmaceutical core tablets
|
EP1408950B1
(en)
*
|
2001-07-11 |
2007-04-25 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Methods of treating cytokine mediated diseases
|
CA2454913A1
(en)
*
|
2001-08-20 |
2003-02-27 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-¬4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl|-urea and a cyclodextrin
|
EP1425261A2
(de)
*
|
2001-08-31 |
2004-06-09 |
Bayer Chemicals AG |
Verfahren zur herstellung von 4-amino-1-naphtholethern
|
JP2005503400A
(ja)
*
|
2001-09-13 |
2005-02-03 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
サイトカイン媒介病の治療方法
|
US6825184B2
(en)
|
2001-10-18 |
2004-11-30 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
1,4-Disubstituted benzo-fused urea compounds
|
CA2465759A1
(en)
*
|
2001-12-11 |
2003-06-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Method for administering birb 796 bs
|
AU2003209118A1
(en)
|
2002-02-11 |
2003-09-04 |
Bayer Pharmaceuticals Corporation |
Aryl ureas as kinase inhibitors
|
WO2003068229A1
(en)
|
2002-02-11 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
|
EP1478358B1
(en)
|
2002-02-11 |
2013-07-03 |
Bayer HealthCare LLC |
Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
|
WO2003068223A1
(en)
*
|
2002-02-11 |
2003-08-21 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenesis inhibiting activity
|
JP4629978B2
(ja)
*
|
2002-02-25 |
2011-02-09 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
サイトカイン媒介疾患の治療に有用な1,4−二置換ベンゾ縮合シクロアルキル尿素化合物
|
US20030225089A1
(en)
*
|
2002-04-10 |
2003-12-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
|
US20030236287A1
(en)
*
|
2002-05-03 |
2003-12-25 |
Piotrowski David W. |
Positive allosteric modulators of the nicotinic acetylcholine receptor
|
WO2004004725A2
(en)
|
2002-07-09 |
2004-01-15 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
|
US20040044020A1
(en)
*
|
2002-07-09 |
2004-03-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors
|
AU2003257991A1
(en)
|
2002-08-08 |
2004-02-25 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
|
US7232828B2
(en)
|
2002-08-10 |
2007-06-19 |
Bethesda Pharmaceuticals, Inc. |
PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
|
US20040110755A1
(en)
*
|
2002-08-13 |
2004-06-10 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
|
WO2004016267A1
(en)
*
|
2002-08-14 |
2004-02-26 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors
|
US7166628B2
(en)
*
|
2002-11-27 |
2007-01-23 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Cytokine inhibitors
|
US20040138216A1
(en)
*
|
2002-12-23 |
2004-07-15 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Process for the preparation of an essentially pure polymorph of an n-pyrazolyl-n'-naphthyl-urea
|
US7279576B2
(en)
|
2002-12-31 |
2007-10-09 |
Deciphera Pharmaceuticals, Llc |
Anti-cancer medicaments
|
US7144911B2
(en)
|
2002-12-31 |
2006-12-05 |
Deciphera Pharmaceuticals Llc |
Anti-inflammatory medicaments
|
US7202257B2
(en)
|
2003-12-24 |
2007-04-10 |
Deciphera Pharmaceuticals, Llc |
Anti-inflammatory medicaments
|
US20080045706A1
(en)
*
|
2002-12-31 |
2008-02-21 |
Flynn Daniel L |
Anti-inflammatory medicaments
|
NZ562413A
(en)
*
|
2003-02-21 |
2009-02-28 |
Resmed Ltd |
Headgear assembly for nasal pillows mask
|
ES2357288T3
(es)
*
|
2003-02-28 |
2011-04-25 |
Bayer Healthcare Llc |
Derivados de 2-oxo-1,3,5-perhidrotriazapina útiles en el tratamiento de angiogénesis hiperproliferativa y trastornos inflamatorios.
|
UY28213A1
(es)
|
2003-02-28 |
2004-09-30 |
Bayer Pharmaceuticals Corp |
Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
|
US7135575B2
(en)
|
2003-03-03 |
2006-11-14 |
Array Biopharma, Inc. |
P38 inhibitors and methods of use thereof
|
GB0320244D0
(en)
*
|
2003-05-06 |
2003-10-01 |
Aventis Pharma Inc |
Pyrazoles as inhibitors of tumour necrosis factor
|
US20070172446A1
(en)
|
2003-05-16 |
2007-07-26 |
Intermune, Inc. |
Synthetic chemokine receptor ligands and methods of use thereof
|
WO2004101529A1
(ja)
*
|
2003-05-19 |
2004-11-25 |
Ono Pharmaceutical Co., Ltd. |
含窒素複素環化合物およびその医薬用途
|
CA2526636C
(en)
|
2003-05-20 |
2012-10-02 |
Bayer Pharmaceuticals Corporation |
Diaryl ureas for diseases mediated by pdgfr
|
US7405210B2
(en)
|
2003-05-21 |
2008-07-29 |
Osi Pharmaceuticals, Inc. |
Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
|
WO2004113352A1
(en)
*
|
2003-06-19 |
2004-12-29 |
Amedis Pharmaceuticals Ltd. |
Silylated heterocyclylurea derivatives as cytokine-inhibitors
|
TWI372050B
(en)
|
2003-07-03 |
2012-09-11 |
Astex Therapeutics Ltd |
(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
|
CL2004001834A1
(es)
|
2003-07-23 |
2005-06-03 |
Bayer Pharmaceuticals Corp |
Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
|
AU2004266719A1
(en)
*
|
2003-08-22 |
2005-03-03 |
Boehringer Ingelheim France S.A.S. |
Methods of treating COPD and pulmonary hypertension
|
AU2004270733B2
(en)
|
2003-09-11 |
2011-05-19 |
Itherx Pharma, Inc. |
Cytokine inhibitors
|
EP1683785B1
(en)
|
2003-11-11 |
2013-10-16 |
Eisai R&D Management Co., Ltd. |
Urea derivative and process for producing the same
|
AU2004291147A1
(en)
|
2003-11-13 |
2005-06-02 |
Ambit Biosciences Corporation |
Urea derivatives as kinase modulators
|
EP1716121A1
(en)
*
|
2003-12-18 |
2006-11-02 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Polymorph of birb 796, a p38map kinase inhibitor
|
US20070191336A1
(en)
*
|
2003-12-24 |
2007-08-16 |
Flynn Daniel L |
Anti-inflammatory medicaments
|
WO2005085245A1
(en)
|
2004-03-08 |
2005-09-15 |
Prosidion Limited |
Pyrrolopyridine-2-carboxylic acid hydrazides
|
MXPA06012394A
(es)
*
|
2004-04-30 |
2007-01-31 |
Bayer Pharmaceuticals Corp |
Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer.
|
PT1761520E
(pt)
*
|
2004-06-23 |
2008-09-15 |
Lilly Co Eli |
Inibidores de quinase
|
EP1609789A1
(en)
*
|
2004-06-23 |
2005-12-28 |
Eli Lilly And Company |
Ureido-pyrazole derivatives and their use as kinase inhibitors
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
AP2326A
(en)
|
2004-08-12 |
2011-11-24 |
Pfizer |
Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors.
|
ES2322175T3
(es)
|
2004-09-17 |
2009-06-17 |
EISAI R&D MANAGEMENT CO., LTD. |
Composicion medicinal con estabilidad mejorada y gelificacion reducida.
|
DE102004055633A1
(de)
*
|
2004-11-12 |
2006-05-18 |
Schering Ag |
5-substituierte Chinolin- und Isochinolin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer
|
BRPI0518432A2
(pt)
*
|
2004-11-17 |
2008-11-25 |
Angiogen Pharmaceuticals Pty L |
mÉtodo de modular o funcionamento de cÉlula b
|
US20080009519A1
(en)
*
|
2004-11-17 |
2008-01-10 |
Lawrence Steinman |
Method of modulating t cell functioning
|
ATE424821T1
(de)
|
2004-12-02 |
2009-03-15 |
Prosidion Ltd |
Pyrrolopyridin-2-karbonsäureamide
|
JP2008523072A
(ja)
|
2004-12-07 |
2008-07-03 |
ルーカス ファーマシューティカルズ, インコーポレイテッド |
タンパク質キナーゼの阻害剤
|
EP1828169A2
(en)
|
2004-12-07 |
2007-09-05 |
Locus Pharmaceuticals, Inc. |
Urea inhibitors of map kinases
|
AU2005321946B2
(en)
|
2004-12-23 |
2012-08-16 |
Deciphera Pharmaceuticals, Llc |
Enzyme modulators and treatments
|
AU2005325676A1
(en)
*
|
2004-12-23 |
2006-08-03 |
Deciphera Pharmaceuticals, Llc |
Anti-inflammatory medicaments
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
JP5507049B2
(ja)
|
2004-12-30 |
2014-05-28 |
アステックス、セラピューティックス、リミテッド |
医薬品
|
EP1881955A1
(en)
*
|
2005-05-12 |
2008-01-30 |
Boehringer Ingelheim International GmbH |
Bis-amination of aryl halides
|
JP4989476B2
(ja)
|
2005-08-02 |
2012-08-01 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
血管新生阻害物質の効果を検定する方法
|
US7714127B2
(en)
*
|
2005-10-06 |
2010-05-11 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Process for making heteroaryl amine intermediate compounds
|
AR058128A1
(es)
*
|
2005-10-28 |
2008-01-23 |
Lilly Co Eli |
Compuesto de pirazolil carbamato y formulacion farmaceutica que lo comprende
|
GB2431927B
(en)
|
2005-11-04 |
2010-03-17 |
Amira Pharmaceuticals Inc |
5-Lipoxygenase-activating protein (FLAP) inhibitors
|
US8399666B2
(en)
|
2005-11-04 |
2013-03-19 |
Panmira Pharmaceuticals, Llc |
5-lipoxygenase-activating protein (FLAP) inhibitors
|
US7977359B2
(en)
|
2005-11-04 |
2011-07-12 |
Amira Pharmaceuticals, Inc. |
5-lipdxygenase-activating protein (FLAP) inhibitors
|
WO2007064872A2
(en)
*
|
2005-12-01 |
2007-06-07 |
Bayer Healthcare Llc |
Urea compounds useful in the treatment of cancer
|
JP5474354B2
(ja)
|
2005-12-30 |
2014-04-16 |
アステックス、セラピューティックス、リミテッド |
医薬化合物
|
CA2635888A1
(en)
*
|
2006-01-04 |
2007-07-19 |
Locus Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
DK1981851T3
(da)
|
2006-01-31 |
2012-03-19 |
Array Biopharma Inc |
Kinaseinhibitorer og fremgangsmåder til anvendelse deraf
|
JP2009526039A
(ja)
*
|
2006-02-10 |
2009-07-16 |
ファイザー・プロダクツ・インク |
ピリジノンピラゾール尿素およびピリミジノンピラゾール尿素誘導体
|
MX2008014289A
(es)
|
2006-05-08 |
2008-11-26 |
Ariad Pharma Inc |
Compuestos heteroarilicos acetilenicos.
|
WO2007133562A2
(en)
|
2006-05-08 |
2007-11-22 |
Ariad Pharmaceuticals, Inc. |
Monocyclic heteroaryl compounds
|
WO2007136103A1
(ja)
|
2006-05-18 |
2007-11-29 |
Eisai R & D Management Co., Ltd. |
甲状腺癌に対する抗腫瘍剤
|
EP2049119A2
(en)
|
2006-06-29 |
2009-04-22 |
Astex Therapeutics Limited |
Pharmaceutical combinations of 1-cyclopropyl-3-[3-(5-morphoolin-4-ylmethyl-1h-benzoimidazol-2-yl)-1h-1-pyrazol-4-yl]-urea
|
WO2008026748A1
(fr)
|
2006-08-28 |
2008-03-06 |
Eisai R & D Management Co., Ltd. |
Agent antitumoral pour cancer gastrique non différencié
|
US8188113B2
(en)
|
2006-09-14 |
2012-05-29 |
Deciphera Pharmaceuticals, Inc. |
Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
US7790756B2
(en)
|
2006-10-11 |
2010-09-07 |
Deciphera Pharmaceuticals, Llc |
Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
|
US7737149B2
(en)
*
|
2006-12-21 |
2010-06-15 |
Astrazeneca Ab |
N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
|
KR101445892B1
(ko)
|
2007-01-29 |
2014-09-29 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
미분화형 위암 치료용 조성물
|
WO2008125014A1
(fr)
*
|
2007-04-13 |
2008-10-23 |
Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. |
Composés d'urée, leurs procédés de préparation et leurs utilisations pharmaceutiques
|
US20110189167A1
(en)
*
|
2007-04-20 |
2011-08-04 |
Flynn Daniel L |
Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
|
WO2008131253A1
(en)
*
|
2007-04-20 |
2008-10-30 |
Deciphera Pharmaceuticals, Llc |
Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
|
EP1992344A1
(en)
|
2007-05-18 |
2008-11-19 |
Institut Curie |
P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
|
US7868001B2
(en)
*
|
2007-11-02 |
2011-01-11 |
Hutchison Medipharma Enterprises Limited |
Cytokine inhibitors
|
US8952035B2
(en)
|
2007-11-09 |
2015-02-10 |
Eisai R&D Management Co., Ltd. |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
EP2111861A1
(en)
|
2008-04-21 |
2009-10-28 |
Ranbaxy Laboratories Limited |
Compositions of phosphodiesterase type IV inhibitors
|
WO2010068311A1
(en)
|
2008-05-23 |
2010-06-17 |
Amira Pharmaceuticals, Inc. |
5-lipoxygenase-activating protein inhibitor
|
US8637575B2
(en)
|
2008-06-05 |
2014-01-28 |
Novotyr Therapeutics Ltd. |
Modulators of protein kinase signaling
|
MX2011003553A
(es)
|
2008-10-02 |
2011-05-25 |
Respivert Ltd |
Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38.
|
GB0818033D0
(en)
*
|
2008-10-02 |
2008-11-05 |
Respivert Ltd |
Novel compound
|
MX2011004535A
(es)
*
|
2008-10-29 |
2011-11-18 |
Deciphera Pharmaceuticals Llc |
Ciclopropanamidas y analogos que exhiben actividades anti-cancer y anti-proliferativas.
|
FR2937973B1
(fr)
*
|
2008-11-04 |
2010-11-05 |
Galderma Res & Dev |
Modulateurs des recepteurs de la melanocortine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
|
WO2010056311A1
(en)
|
2008-11-12 |
2010-05-20 |
Ariad Pharmaceuticals, Inc. |
Pyrazinopyrazines and derivatives as kinase inhibitors
|
EP2370428B1
(en)
|
2008-12-11 |
2016-08-10 |
Respivert Limited |
P38 map kinase inhibitors
|
CA2756067A1
(en)
|
2009-03-27 |
2010-09-30 |
Pathway Therapeutics, Inc. |
Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
|
GB0905955D0
(en)
|
2009-04-06 |
2009-05-20 |
Respivert Ltd |
Novel compounds
|
PL2484661T3
(pl)
|
2009-09-30 |
2017-10-31 |
Toray Industries |
Pochodna 2,3-dihydro-1h-inden-2-ylomocznika i jej zastosowanie farmaceutyczne
|
GB0921730D0
(en)
|
2009-12-11 |
2010-01-27 |
Respivert Ltd |
Method of treatment
|
GB0921731D0
(en)
|
2009-12-11 |
2010-01-27 |
Respivert Ltd |
Theraputic uses
|
GB201005589D0
(en)
|
2010-04-01 |
2010-05-19 |
Respivert Ltd |
Novel compounds
|
FR2993780B1
(fr)
*
|
2012-07-26 |
2015-02-13 |
Assist Publ Hopitaux De Paris |
Methode de traitement de la sclerose en plaque
|
JP5787977B2
(ja)
|
2010-04-08 |
2015-09-30 |
レスピバート・リミテツド |
P38mapキナーゼ阻害剤
|
JP5787976B2
(ja)
|
2010-04-08 |
2015-09-30 |
レスピバート・リミテツド |
P38mapキナーゼ阻害剤としてのピラゾリルウレア
|
WO2011150198A1
(en)
|
2010-05-27 |
2011-12-01 |
Ambit Biosciences Corporation |
Azolyl urea compounds and methods of use thereof
|
GB201009731D0
(en)
*
|
2010-06-10 |
2010-07-21 |
Pulmagen Therapeutics Inflamma |
Kinase inhibitors
|
US8933228B2
(en)
|
2010-06-17 |
2015-01-13 |
Respivert, Ltd. |
Respiratory formulations and compounds for use therein
|
BR112012032462A2
(pt)
|
2010-06-25 |
2016-11-08 |
Eisai R&D Man Co Ltd |
agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
|
US9090592B2
(en)
*
|
2010-12-30 |
2015-07-28 |
AbbVie Deutschland GmbH & Co. KG |
Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
|
US8962650B2
(en)
|
2011-04-18 |
2015-02-24 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
NZ618795A
(en)
|
2011-05-13 |
2015-07-31 |
Array Biopharma Inc |
Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
|
EP3444363B1
(en)
|
2011-06-03 |
2020-11-25 |
Eisai R&D Management Co., Ltd. |
Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
MY167798A
(en)
|
2011-10-03 |
2018-09-26 |
Respivert Ltd |
1-pyrazolyl-3- (4- ( (2 -anilinopyrimidin- 4 - yl) oxy) napththalen- 1 - yl) ureas as p38 map kinase inhibitors
|
EP2578582A1
(en)
|
2011-10-03 |
2013-04-10 |
Respivert Limited |
1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
|
US8685418B2
(en)
|
2011-10-24 |
2014-04-01 |
Endo Pharmaceuticals Inc. |
Cyclohexylamines
|
KR20140103925A
(ko)
*
|
2011-12-09 |
2014-08-27 |
키에시 파르마슈티시 엣스. 피. 에이. |
4-히드록시-1,2,3,4-테트라히드로나프탈렌-1-일 우레아 및 호흡기 질환의 치료에서의 이들의 용도
|
EP3553169B1
(en)
|
2011-12-28 |
2021-11-03 |
Kyoto Prefectural Public University Corporation |
Normalization of culture of corneal endothelial cells
|
US8461179B1
(en)
|
2012-06-07 |
2013-06-11 |
Deciphera Pharmaceuticals, Llc |
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
GB201214750D0
(en)
|
2012-08-17 |
2012-10-03 |
Respivert Ltd |
Compounds
|
EP2890460B1
(en)
|
2012-08-29 |
2017-02-22 |
Respivert Limited |
Kinase inhibitors
|
WO2014033447A2
(en)
|
2012-08-29 |
2014-03-06 |
Respivert Limited |
Kinase inhibitors
|
WO2014033449A1
(en)
|
2012-08-29 |
2014-03-06 |
Respivert Limited |
Kinase inhibitors
|
GB201215357D0
(en)
|
2012-08-29 |
2012-10-10 |
Respivert Ltd |
Compounds
|
US9790178B2
(en)
|
2012-11-13 |
2017-10-17 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
DK2922844T3
(en)
|
2012-11-13 |
2018-03-05 |
Array Biopharma Inc |
N-PYRROLIDINYL, N'-PYRAZOLYL-URINE, THIOURINE, GUANIDINE AND CYANOGUANIDE COMPOUNDS AS TRKA-KINASE INHIBITORS
|
LT2920166T
(lt)
|
2012-11-13 |
2016-12-12 |
Array Biopharma, Inc. |
Bicikliniai karbamido, tiokarbamido, guanidino ir cianoguanidino junginiai, tinkami naudoti skausmo gydymui
|
WO2014078378A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
US9809578B2
(en)
|
2012-11-13 |
2017-11-07 |
Array Biopharma Inc. |
Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors
|
WO2014078322A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
US9546156B2
(en)
|
2012-11-13 |
2017-01-17 |
Array Biopharma Inc. |
N-bicyclic aryl,N'-pyrazolyl urea, thiourea, guanidine cyanoguanidine compounds as TrkA kinase inhibitors
|
WO2014078408A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
WO2014078325A1
(en)
|
2012-11-13 |
2014-05-22 |
Array Biopharma Inc. |
N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors
|
US9969694B2
(en)
|
2012-11-13 |
2018-05-15 |
Array Biopharma Inc. |
N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors
|
WO2014076484A1
(en)
|
2012-11-16 |
2014-05-22 |
Respivert Limited |
Kinase inhibitors
|
MX2015004979A
(es)
|
2012-12-21 |
2015-07-17 |
Eisai R&D Man Co Ltd |
Forma amorfa de derivado de quinolina y metodo para su produccion.
|
EP2970190A1
(en)
|
2013-03-14 |
2016-01-20 |
Respivert Limited |
Kinase inhibitors
|
WO2014162121A1
(en)
|
2013-04-02 |
2014-10-09 |
Topivert Pharma Limited |
Kinase inhibitors based upon n-alkyl pyrazoles
|
CN105408315B
(zh)
|
2013-04-02 |
2018-09-14 |
瑞斯比维特有限公司 |
激酶抑制剂
|
ES2687968T3
(es)
|
2013-05-14 |
2018-10-30 |
Eisai R&D Management Co., Ltd. |
Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
|
CA2914457A1
(en)
*
|
2013-06-06 |
2014-12-11 |
Chiesi Farmaceutici S.P.A. |
Kinase inhibitors
|
WO2015008206A1
(en)
|
2013-07-14 |
2015-01-22 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Igf-1r signaling pathway inhibitors useful in the treatment of neurodegenerative diseases
|
EP3069732B1
(en)
|
2013-11-14 |
2023-07-12 |
The Doshisha |
Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage
|
US9890185B2
(en)
|
2013-12-20 |
2018-02-13 |
Respivert Limited |
Urea derivatives useful as kinase inhibitors
|
CN113264921B
(zh)
|
2014-02-14 |
2024-09-13 |
瑞斯比维特有限公司 |
作为激酶抑制剂的吡唑基-脲
|
LT3154959T
(lt)
|
2014-05-15 |
2019-09-25 |
Array Biopharma, Inc. |
1-((3s,4r)-4-(3-fluorfenil)-1-(2-metoksietil)pirolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)karbamidas kaip trka kinazės inhibitorius
|
CA2949004A1
(en)
|
2014-05-16 |
2015-11-19 |
Atriva Therapeutics Gmbh |
Novel anti-infective strategy against influenza virus and s. aureus coinfections
|
BR112017002827B1
(pt)
|
2014-08-28 |
2023-04-18 |
Eisai R&D Management Co., Ltd |
Derivado de quinolina altamente puro e método para produção do mesmo
|
MY190027A
(en)
|
2014-08-29 |
2022-03-22 |
Torrent Pharmaceuticals Ltd |
P38 map kinase inhibiting indanyl urea compounds
|
MA40774A
(fr)
|
2014-10-01 |
2017-08-08 |
Respivert Ltd |
Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
|
EP3750530A1
(en)
|
2015-02-05 |
2020-12-16 |
TyrNovo Ltd. |
Combinations of irs/stat3 dual modulators and anti-cancer agents for treating cancer
|
MX2017010474A
(es)
|
2015-02-25 |
2017-11-28 |
Eisai R&D Man Co Ltd |
Metodo para suprimir el amargor de un derivado de quinoleina.
|
KR20240064733A
(ko)
|
2015-03-04 |
2024-05-13 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
SG11201710198YA
(en)
|
2015-06-16 |
2018-01-30 |
Eisai R&D Man Co Ltd |
Anticancer agent
|
WO2017151409A1
(en)
|
2016-02-29 |
2017-09-08 |
University Of Florida Research Foundation, Incorporated |
Chemotherapeutic methods
|
CA3015978A1
(en)
|
2016-04-06 |
2017-10-12 |
Topivert Pharma Limited |
Kinase inhibitors
|
EP3582781A4
(en)
|
2017-02-15 |
2020-12-09 |
The University of Melbourne |
TREATMENT PROCEDURES
|
AU2018257203B2
(en)
*
|
2017-04-27 |
2022-05-26 |
Mochida Pharmaceutical Co., Ltd. |
Novel tetrahydronaphthyl urea derivatives
|
US10342786B2
(en)
|
2017-10-05 |
2019-07-09 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
|
WO2019071144A1
(en)
|
2017-10-05 |
2019-04-11 |
Fulcrum Therapeutics, Inc. |
USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION
|
SG11202007198WA
(en)
|
2018-01-31 |
2020-08-28 |
Deciphera Pharmaceuticals Llc |
Combination therapy for the treatment of gastrointestinal stromal tumors
|
CN111548313A
(zh)
*
|
2019-02-11 |
2020-08-18 |
绍兴从零医药科技有限公司 |
预防和治疗慢性疼痛药物的胍类化合物
|
ES2789898B2
(es)
|
2019-04-25 |
2021-10-14 |
Fund Profesor Novoa Santos |
Composicion para el tratamiento de los efectos secundarios de la radioterapia y/o quimioterapia
|
TW202112368A
(zh)
|
2019-06-13 |
2021-04-01 |
荷蘭商法西歐知識產權股份有限公司 |
用於治療有關dux4表現之疾病的抑制劑組合
|
BR112022002609A2
(pt)
|
2019-08-12 |
2022-08-09 |
Deciphera Pharmaceuticals Llc |
Métodos de tratamento de tumores estromais gastrointestinais
|
WO2021030405A1
(en)
|
2019-08-12 |
2021-02-18 |
Deciphera Pharmaceuticals, Llc |
Ripretinib for treating gastrointestinal stromal tumors
|
DK4084778T3
(da)
|
2019-12-30 |
2023-12-11 |
Deciphera Pharmaceuticals Llc |
Amorfe kinaseinhibitorformuleringer og fremgangsmåder til anvendelse deraf
|
KR20220123058A
(ko)
|
2019-12-30 |
2022-09-05 |
데시페라 파마슈티칼스, 엘엘씨. |
1-(4-브로모-5-(1-에틸-7-(메틸아미노)-2-옥소-1,2-디히드로-1,6-나프티리딘-3-일)-2-플루오로페닐)-3-페닐우레아의 조성물
|
CN112961120B
(zh)
*
|
2021-02-06 |
2022-02-08 |
河南省锐达医药科技有限公司 |
一种萘基脲类化合物、其制备方法及应用
|
WO2023280911A1
(en)
|
2021-07-06 |
2023-01-12 |
Westfälische Wilhelms-Universität Münster |
P38-inhibitors for the treatment of coronavirus infections and/or covid-19 cytokine storm
|
CN114702439B
(zh)
*
|
2021-12-13 |
2023-11-10 |
河南省锐达医药科技有限公司 |
一类萘基脲-哌嗪类化合物及其制备方法和应用
|
US11779572B1
(en)
|
2022-09-02 |
2023-10-10 |
Deciphera Pharmaceuticals, Llc |
Methods of treating gastrointestinal stromal tumors
|